Search
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...
Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLECategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent tha...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalPitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessiv...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalMyelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesIcotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Early research into cabotegravir showed it had lower oral bioavailability than dolutegr...
Categories: P-glycoprotein substratesTalazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib wa...
Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index